BACKGROUND AND PURPOSE: After acute stroke, an increased level of C-reactive protein (CRP) measured at discharge predicts unfavorable outcome. We sought to investigate whether CRP measured before tissue plasminogen activator (tPA) treatments may add prognostic information to guide stroke thrombolysis. METHODS: Our target was 151 consecutive patients with an ischemic stroke involving the middle cerebral artery territory who received tPA within 3 hours of symptom onset. High-sensitivity CRP was measured before tPA administration, and CRP gene polymorphisms were determined (G1059C and C1444T). Functional outcome was evaluated by 3-month modified Rankin Scale (mRS). RESULTS: A total of 143 tPA-treated patients were valid for analyses after exclusion of those with inflammatory diseases and those probably infected (CRP >6 mg/dL). Patients with history of previous stroke, hypertension, or atrial fibrillation had higher levels of CRP (P<0.05). CRP was higher in patients who died after thrombolysis (n=19) than in survivors (0.85 versus 0.53 mg/dL; P=0.002). Among the 94 patients with proximal middle cerebral artery occlusions, CRP level was 0.53 for 81 survivors versus 0.81 mg/dL for 13 who died (P=0.001). CRP-survival association was found even among patients who recanalized by the end of tPA infusion (P=0.007). A correlation between CRP and mRS was found (r=0.36, P=0.02), although CRP polymorphisms were not related to neurological outcome. In a logistic regression model, CRP (odds ratio=8.51; 95% CI, 2.16 to 33.5; P=0.002) and age (odds ratio=6.25; 95% CI, 1.44 to 27.19; P=0.015) were the only baseline mortality predictors. CONCLUSIONS: Admission CRP predicts mortality among tPA-treated stroke patients. Very early recanalization does not ameliorate the negative prognostic impact of elevated CRP.
BACKGROUND AND PURPOSE: After acute stroke, an increased level of C-reactive protein (CRP) measured at discharge predicts unfavorable outcome. We sought to investigate whether CRP measured before tissue plasminogen activator (tPA) treatments may add prognostic information to guide stroke thrombolysis. METHODS: Our target was 151 consecutive patients with an ischemic stroke involving the middle cerebral artery territory who received tPA within 3 hours of symptom onset. High-sensitivity CRP was measured before tPA administration, and CRP gene polymorphisms were determined (G1059C and C1444T). Functional outcome was evaluated by 3-month modified Rankin Scale (mRS). RESULTS: A total of 143 tPA-treated patients were valid for analyses after exclusion of those with inflammatory diseases and those probably infected (CRP >6 mg/dL). Patients with history of previous stroke, hypertension, or atrial fibrillation had higher levels of CRP (P<0.05). CRP was higher in patients who died after thrombolysis (n=19) than in survivors (0.85 versus 0.53 mg/dL; P=0.002). Among the 94 patients with proximal middle cerebral artery occlusions, CRP level was 0.53 for 81 survivors versus 0.81 mg/dL for 13 who died (P=0.001). CRP-survival association was found even among patients who recanalized by the end of tPA infusion (P=0.007). A correlation between CRP and mRS was found (r=0.36, P=0.02), although CRP polymorphisms were not related to neurological outcome. In a logistic regression model, CRP (odds ratio=8.51; 95% CI, 2.16 to 33.5; P=0.002) and age (odds ratio=6.25; 95% CI, 1.44 to 27.19; P=0.015) were the only baseline mortality predictors. CONCLUSIONS: Admission CRP predicts mortality among tPA-treated strokepatients. Very early recanalization does not ameliorate the negative prognostic impact of elevated CRP.
Authors: Ana Luisa Miranda-Vilela; Arthur K Akimoto; Graciana S Lordelo; Luiz C S Pereira; Cesar K Grisolia; Maria de Nazaré Klautau-Guimarães Journal: Eur J Appl Physiol Date: 2011-04-23 Impact factor: 3.078
Authors: Tiago Krug; João Paulo Gabriel; Ricardo Taipa; Benedita V Fonseca; Sophie Domingues-Montanari; Israel Fernandez-Cadenas; Helena Manso; Liliana O Gouveia; João Sobral; Isabel Albergaria; Gisela Gaspar; Jordi Jiménez-Conde; Raquel Rabionet; José M Ferro; Joan Montaner; Astrid M Vicente; Mário Rui Silva; Ilda Matos; Gabriela Lopes; Sofia A Oliveira Journal: J Cereb Blood Flow Metab Date: 2012-03-28 Impact factor: 6.200
Authors: Ana Luisa Miranda-Vilela; Arthur K Akimoto; Graciana S Lordelo; Luiz C S Pereira; Cesar K Grisolia; Maria de Nazaré Klautau-Guimarães Journal: Eur J Appl Physiol Date: 2011-06-26 Impact factor: 3.078
Authors: K Rajeshwar; Subhash Kaul; Amal Al-Hazzani; M Sai Babu; N Balakrishna; Vandana Sharma; A Jyothy; Anjana Munshi Journal: Inflammation Date: 2012-06 Impact factor: 4.092
Authors: Reyna L VanGilder; Danielle M Davidov; Kyle R Stinehart; Jason D Huber; Ryan C Turner; Karen S Wilson; Eric Haney; Stephen M Davis; Paul D Chantler; Laurie Theeke; Charles L Rosen; Todd J Crocco; Laurie Gutmann; Taura L Barr Journal: J Clin Neurosci Date: 2013-08-23 Impact factor: 1.961
Authors: H M den Hertog; J A van Rossum; H B van der Worp; H M A van Gemert; R de Jonge; P J Koudstaal; D W J Dippel Journal: J Neurol Date: 2009-12 Impact factor: 4.849